New NICE guidance March 2011

This guidance replaces NICE technology appraisal guidance 111 issued in November 2006 (amended September 2007, August 2009). The review and re-appraisal of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease has resulted in a change in the guidance.

Microsoft Word Document icon 16667.doc — Microsoft Word Document, 40 KB (41472 bytes) application/msword, 40.5 KB

Source: http://guidance.nice.org.uk/TA217
Date: 6 April 2011